The passage of the JOBS and Investor Confidence Act (Jobs Act 3.0) in the U.S. House of Representatives on July 17 may mark the end of the GOP’s efforts to repeal Dodd-Frank.
Will Help Clients Achieve Business Goals in Statehouses Nationwide
Michael Drobac, a senior advisor in McGuireWoods Consulting’s Washington, D.C., office and head of its emerging technologies team, was quoted in a July 6 Politico Pro Transportation story on how the commercial drone industry is affected by a stalemate over new rules governing model aircraft.
Michele Satterlund, McGuireWoods partner and senior vice president at McGuireWoods Consulting, recently wrote a comprehensive overview of legislative battles waged in state capitals across the nation over efforts to ban or restrict ocular telehealth — eye care services via telecommunications technology such as smartphones.
The Virginia Supreme Court recently found a 15-year lease unenforceable because it was not executed with the formalities of a “deed” in accordance with Virginia law.
Bill of the Week: Tax Cuts 2.0
Well…it’s not going to be an actual bill: Ways and Means Chairman Kevin Brady (R-TX) will release an outline for Tax Cuts 2.0 before the House departs for August recess this week. House GOP tax writers are meeting one more time before the rollout.
This Week: More rules to OMB…House overhauls OTC drug rules…HELP Committee looks at drug costs…FDA outlines reorganization
Your weekly North Carolina political news report.
Final day for early voting - what you should know
Word of the Week: Bureaucracy
The OMB and Treasury issued a memorandum of agreement (MOA) in April that established a new interagency process for reviewing certain tax regulations, namely those stemming from the 2017 GOP tax law. And things are working as expected…
An overview of the upcoming week in Congress from the McGuireWoods Consulting Federal Public Affairs Team.
The Centers for Medicare and Medicaid Services (CMS) recently proposed to expand its site-neutral payment policy to clinic visits.
The House of Representatives approved the first major change to federal regulation of the over-the-counter drug industry in 40 years.